{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:04:12Z","timestamp":1761930252043,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China\/Youth Science Foundation Project","award":["(82102426)"],"award-info":[{"award-number":["(82102426)"]}]},{"name":"Zhejiang Natural Science Foundation\/Youth Fund Project","award":["(LQ22H190001)"],"award-info":[{"award-number":["(LQ22H190001)"]}]},{"name":"State Key Laboratory of Veterinary Etiological Biology Open Fund","award":["(SKLVEB2021KFKT007)"],"award-info":[{"award-number":["(SKLVEB2021KFKT007)"]}]},{"DOI":"10.13039\/100007834","name":"Ningbo Natural Science Foundation","doi-asserted-by":"crossref","award":["(2021J103)"],"award-info":[{"award-number":["(2021J103)"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>UK-5099 is a potent mitochondrial acetone carrier inhibitor, that exhibits anticancer activity. Recently, the anti-<jats:italic>Toxoplasma gondii<\/jats:italic> activity of UK-5099 was proposed, and in vivo studies of its pharmacokinetics in BALB\/c mice are necessary to further evaluate the clinical effect of UK-5099.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>A simple and fast high-performance liquid chromatography-tandem mass spectrometry (HPLC\u2013MS\/MS) analysis method was established and verified in terms of its linearity, matrix effect, accuracy, precision, recovery and stability. The analytes were separated by an Agilent ZORBAX XDB-C18 column (2.1\u2009\u00d7\u200950\u00a0mm, 3.5\u00a0\u03bcm) at 30\u00a0\u00b0C. A gradient mobile phase consisting of water with 0.1% formic acid (FA) (phase A) and acetonitrile (ACN) (phase B) was delivered at a flow rate of 0.40\u00a0mL\u00b7min<jats:sup>\u22121<\/jats:sup> with an injection volume of 5 \u03bcL. A good linear response was obtained in a concentration range of 5\u20135000\u00a0ng\u00b7mL<jats:sup>\u22121<\/jats:sup> (<jats:italic>r<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.9947). The lower limit of quantification (LLOQ) was 5\u00a0ng\u00b7mL<jats:sup>\u22121<\/jats:sup>. The extraction recovery of UK-5099 was greater than 95%. The inter- and intra-day accuracy and precision of the method showed relative standard deviations (RSDs) of less than 15%. This method has been successfully applied to the pharmacokinetic evaluation of UK-5099 in mouse plasma. In health mice, the main pharmacokinetic parameters of UK-5099 after intraperitoneal administration were measured using a noncompartmental model, in which the AUC<jats:sub>0-t<\/jats:sub> was 42,103\u2009\u00b1\u200912,072\u00a0ng\u00b7h\u00b7mL<jats:sup>\u22121<\/jats:sup> and the MRT<jats:sub>0-t<\/jats:sub> was 0.857\u2009\u00b1\u20090.143\u00a0h. The peak concentration (C<jats:sub>max<\/jats:sub>) was 82,500\u2009\u00b1\u200920,745\u00a0ng\u00b7h\u00b7mL<jats:sup>\u22121<\/jats:sup>, which occurred at a peak time (T<jats:sub>max<\/jats:sub>)\u2009=\u20090.250\u2009\u00b1\u20090.000\u00a0h.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A fast and sensitive HPLC\u2013MS\/MS method was developed, validated and successfully used for the determination of UK-5099 levels in mice after intraperitoneal administration. This study was the first report of the pharmacokinetic parameters of UK-5099 in mice, which will help to further study the administration of UK-5099 in animals and humans.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12917-022-03245-0","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T08:04:08Z","timestamp":1650441848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Determination and pharmacokinetics study of UK-5099 in mouse plasma by LC\u2013MS\/MS"],"prefix":"10.1186","volume":"18","author":[{"given":"Qingyuan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongfei","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinnian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biqing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"issue":"2","key":"3245_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1042\/bj2470441","volume":"247","author":"MO Proudlove","year":"1987","unstructured":"Proudlove MO, Beechey RB, Moore AL. Pyruvate transport by thermogenic-tissue mitochondria. Biochem J. 1987;247(2):441\u20137.","journal-title":"Biochem J"},{"issue":"1","key":"3245_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1042\/bj1480085","volume":"148","author":"AP Halestrap","year":"1975","unstructured":"Halestrap AP. The mitochondrial pyruvate carrier Kinetics and specificity for substrates and inhibitors. Biochem J. 1975;148(1):85\u201396.","journal-title":"Biochem J"},{"key":"3245_CR3","first-page":"193","volume":"43","author":"L Simchowitz","year":"1988","unstructured":"Simchowitz L. Properties of the principal anion-exchange mechanism in human neutrophils. Soc Gen Physiol Ser. 1988;43:193\u2013208.","journal-title":"Soc Gen Physiol Ser"},{"issue":"35","key":"3245_CR4","doi-asserted-by":"publisher","first-page":"37758","DOI":"10.18632\/oncotarget.5386","volume":"6","author":"Y Zhong","year":"2015","unstructured":"Zhong Y, Li X, Yu D, Li X, Li Y, Long Y, et al. Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. Oncotarget. 2015;6(35):37758\u201369.","journal-title":"Oncotarget"},{"issue":"10","key":"3245_CR5","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/anie.201914391","volume":"59","author":"Y Yamashita","year":"2020","unstructured":"Yamashita Y, Vinogradova EV, Zhang X, Suciu RM, Cravatt BF. A chemical proteomic probe for the mitochondrial pyruvate carrier complex. Angew Chem Int Ed Engl. 2020;59(10):3896\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"3245_CR6","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.18632\/oncotarget.13717","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Li X, Kan Q, Zhang M, Li X, Xu R, et al. Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas. Oncotarget. 2017;8(1):1058\u201373.","journal-title":"Oncotarget"},{"issue":"17","key":"3245_CR7","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.3390\/cancers13174278","volume":"13","author":"C Buyse","year":"2021","unstructured":"Buyse C, Joudiou N, Corbet C, Feron O, Mignion L, Flament J, et al. Impact of inhibition of the mitochondrial pyruvate carrier on the tumor extracellular pH as measured by CEST-MRI. Cancers. 2021;13(17):4278.","journal-title":"Cancers."},{"issue":"3","key":"3245_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1042\/bj2230677","volume":"223","author":"AP Halestrap","year":"1984","unstructured":"Halestrap AP, Armston AE. A re-evaluation of the role of mitochondrial pyruvate transport in the hormonal control of rat liver mitochondrial pyruvate metabolism. Biochem J. 1984;223(3):677\u201385.","journal-title":"Biochem J"},{"issue":"4","key":"3245_CR9","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1021\/acs.jmedchem.0c01570","volume":"64","author":"X Liu","year":"2021","unstructured":"Liu X, Flores AA, Situ L, Gu W, Ding H, Christofk HR, et al. Development of novel mitochondrial pyruvate carrier inhibitors to treat hair loss. J Med Chem. 2021;64(4):2046\u201363.","journal-title":"J Med Chem"},{"issue":"9","key":"3245_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/ncb3575","volume":"19","author":"A Flores","year":"2017","unstructured":"Flores A, Schell J, Krall AS, Jelinek D, Miranda M, Grigorian M, et al. Lactate dehydrogenase activity drives hair follicle stem cell activation. Nat Cell Biol. 2017;19(9):1017\u201326.","journal-title":"Nat Cell Biol"},{"issue":"Pt 2","key":"3245_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1042\/bj3120479","volume":"312","author":"EA Wiemer","year":"1995","unstructured":"Wiemer EA, Michels PA, Opperdoes FR. The inhibition of pyruvate transport across the plasma membrane of the bloodstream form of Trypanosoma brucei and its metabolic implications. Biochem J. 1995;312(Pt 2):479\u201384.","journal-title":"Biochem J"},{"issue":"2","key":"3245_CR12","first-page":"1710","volume":"18","author":"D Wang","year":"2018","unstructured":"Wang D, Wang Q, Yan G, Qiao Y, Zhu B, Liu B, et al. Hypoxia induces lactate secretion and glycolytic efflux by downregulating mitochondrial pyruvate carrier levels in human umbilical vein endothelial cells. Mol Med Rep. 2018;18(2):1710\u20137.","journal-title":"Mol Med Rep"},{"issue":"9","key":"3245_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/ncb3593","volume":"19","author":"JC Schell","year":"2017","unstructured":"Schell JC, Wisidagama DR, Bensard C, Zhao H, Wei P, Tanner J, et al. Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism. Nat Cell Biol. 2017;19(9):1027\u201336.","journal-title":"Nat Cell Biol"},{"key":"3245_CR14","unstructured":"Food and Drug Administration of the United States. Guidance for Industry\u2014Bioanalytical Method Validation; US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM): Rockville, USA. 2001."},{"issue":"12","key":"3245_CR15","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1002\/bmc.3001","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang X, Chen M, Wen C, Zhang Q, Ma J. Determination of chidamide in rat plasma by LC-MS and its application to pharmacokinetics study. Biomedical chromatography: BMC. 2013;27(12):1801\u20136.","journal-title":"Biomedical chromatography: BMC"},{"key":"3245_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jpba.2017.11.031","volume":"149","author":"A Singh","year":"2018","unstructured":"Singh A, Thatikonda T, Kumar A, Wazir PVV, Nandi U, Singh PP, et al. Determination of ZSTK474, a novel Pan PI3K inhibitor in mouse plasma by LC-MS\/MS and its application to Pharmacokinetics. J Pharm Biomed Anal. 2018;149:387\u201393.","journal-title":"J Pharm Biomed Anal"},{"key":"3245_CR17","doi-asserted-by":"publisher","first-page":"e3825","DOI":"10.1002\/bmc.3825","volume":"31","author":"B Li","year":"2017","unstructured":"Li B, Gong SY, Zhou XZ, Yang YJ, Li JY, Wei XJ, et al. Determination of antibacterial agent tilmicosin in pig plasma by LC\/MS\/MS and its application to pharmacokinetics. Biomed Chromatogr. 2017;31:e3825.","journal-title":"Biomed Chromatogr."},{"issue":"5","key":"3245_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2125.1994.tb05705.x","volume":"37","author":"N Baber","year":"2012","unstructured":"Baber N. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). British J Clin Pharmacol. 2012;37(5):401\u20134.","journal-title":"British J Clin Pharmacol"},{"key":"3245_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12917-021-02990-y","volume":"17","author":"JL Zhang","year":"2021","unstructured":"Zhang JL, Si HF, Sun JC, Lv K, Yan BQ, Li B, et al. Determination of myrislignan levels in BALB\/c mouse plasma by LC-MS\/MS and a comparison of its pharmacokinetics after oral and intraperitoneal administration. BMC Vet Res. 2021;17:275.","journal-title":"BMC Vet Res"},{"key":"3245_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12917-019-1963-0","volume":"15","author":"JL Zhang","year":"2019","unstructured":"Zhang JL, Bai YB, Li B, Zhou XZ, Si HF, Zhang JY. Determination and pharmacokinetics study of oxyclozanide suspension in cattle by LC-MS\/MS. BMC Vet Res. 2019;15:210.","journal-title":"BMC Vet Res"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-022-03245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-022-03245-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-022-03245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:11:43Z","timestamp":1650539503000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-022-03245-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3245"],"URL":"https:\/\/doi.org\/10.1186\/s12917-022-03245-0","relation":{},"ISSN":["1746-6148"],"issn-type":[{"type":"electronic","value":"1746-6148"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was carried out in compliance with the ARRIVE guidelines. The study, executed by Dr. Jili Zhang was conducted between March and April 2020 at the Lanzhou Institute of Husbandry and Pharmaceutical Sciences of Lanzhou, Gansu Province, China. Nine mice were used in this study. All of the experimental methods, the animal care and the barn environment of this study strictly complied with the Guide for the Care and Use of Laboratory Animals, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, China. In addition, all efforts were made to minimize suffering. We agreed to conduct the experiment according to these guidelines, and the certificate number was SCXK (Gan) 2020\u20130005.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}